Victoria Johnson

However, subgroup analyses may reveal a more pronounced effect in people with severe COPD.

CRN declined from 23.2% to 13.1% between 2011 and 2022 but still affects around 2.5 million adults in the US.

The lower BHI observed was likely associated with effects on the musculoskeletal system and not the central nervous system.

New findings cast doubt on required black box warnings for montelukast (brand name Singulair).

Infection and injury were the most common responsible diagnoses for patinets with both PsA or AS.

Meteorological conditions’ effect on exacerbations were likely mediated by particulate matter.

Cancer risk was examined for breast, colorectal, lung, and prostate cancer.

A post-hoc analysis evaluated pooled data from 4 trials of pegloticase.

Heat therapy often worsened symptoms in a randomized controlled trial.

Current asthma diagnosis requires specialized breathing tests that can be challenging for young children.

A VR exergame may facilitate patients’ physical activity while promoting relaxation and positive mental states.

Within 2 years of death, fall-risk increasing drug burden was associated with greater odds of an injurious fall.

Recommendations have been largely preserved since 2018 and the USPSTF acknowledged the need for more research and better risk assessment tools.

However, gout flare states of patient acceptable symptom state, low disease activity, or not achieving either were not associated with EQ-5D-3L or HAQ.

Investigators found an incidence of 26.2 severe infections per 100 patient-years with 4 deaths in the study.

Small molecule drugs may help fill gaps in treatment with biologic therapies.

Tocilizumab and other biological drugs were particularly efficacious in lowering overall hemostatic potential, mitigating blood clot risks.

Around 37% of those had never used a bDMARD reached sustained DMARD-free remission at 5 years,

Piatek discussed findings from a healthcare resource utilization study and a sentiment analysis study presented at ASH 2024.

The biosimilars month in review highlights a newly approved ustekinumab biosimilar and a look into the field in 2024.

CT-P42 may help improve access to aflibercept in lower-income countries.

Despite improvements in PROs and disease activity, no statistically significant changes have been seen on blood biomarker analysis.

The rheumatology month in review emphasizes new research in PsA and on cardiovascular events in rheumatic disease.

An active comparator study found that incident use of gabapentin was associated with lower rates of falls than duloxetine and similar rates of severe falls.

Pipe discussed a symposium at ASH 2024 about practical implementation of gene therapy in the field.

Schultz discussed the SCtalk trial and its findings at ASH 2024.

Less than half of rheumatologists self-reported adhering to febuxostat and allopurinol dosing recommendations.

Zaheer discussed how this research may be used as a model to help study other therapy transitions as well.

Other recent research presented at ACR 2024 found increased CVD risk with glucocorticosteroid use.